Haleon PLC Sponsored ADR (NYSE:HLN) Stock Now Rated “Moderate Buy” by Wall Street Analysts

Shares of Haleon PLC Sponsored ADR (NYSE:HLN) have been assigned an average recommendation of “Moderate Buy” from the ten research firms that are presently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation, three have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $4.90.

HLN has been the topic of a number of research reports. Zacks Research lowered shares of Haleon from a “hold” rating to a “strong sell” rating in a research note on Thursday, October 22nd. Morgan Stanley reissued an “overweight” rating on shares of Haleon in a research report on Thursday, August 6th. Wall Street Zen downgraded shares of Haleon from a “buy” rating to a “hold” rating in a research note on Saturday, October 3rd. Weiss Ratings reiterated a “hold (c)” rating on shares of Haleon in a research report on Friday, September 25th. Finally, Berenberg Bank reaffirmed a “buy” rating on shares of Haleon in a research report on Wednesday, August 5th.

Haleon Trading Down 1.2%

NYSE:HLN opened at $10.08 on Friday. Haleon has a 12 month low of $8.65 and a 12 month high of $11.28. The company has a market capitalization of $44.38 billion, a P/E ratio of 25.84 and a beta of 0.14. The firm has a fifty day simple moving average of $9.59 and a 200-day simple moving average of $9.79.

Haleon Cuts Dividend

The firm also recently disclosed a dividend, which was paid on Thursday, September 17th. Stockholders of record on Friday, August 14th were issued a dividend of $0.0642 per share. This represents a dividend yield of 132.0%. This is a negative change from Haleon’s previous dividend of $0.1307. The ex-dividend date was Friday, August 14th. Haleon’s payout ratio is 30.77%.

Hedge Funds Weigh In On Haleon

A number of institutional investors and hedge funds have recently bought and sold shares of HLN. Root Financial Partners LLC acquired a new stake in shares of Haleon in the 3rd quarter valued at about $25,000. Western Wealth Management LLC bought a new position in shares of Haleon in the first quarter worth $29,000. Annis Gardner Whiting Capital Advisors LLC boosted its stake in Haleon by 402.0% during the 1st quarter. Annis Gardner Whiting Capital Advisors LLC now owns 3,002 shares of the company’s stock valued at $30,000 after purchasing an additional 2,404 shares in the last quarter. Parkside Financial Bank & Trust lifted its holdings in Haleon by 20.4% in the 2nd quarter. Parkside Financial Bank & Trust now owns 6,233 shares of the company’s stock valued at $58,000 after acquiring an additional 1,055 shares during the last quarter. Finally, Fiduciary Financial Group LLC bought a new stake in shares of Haleon during the 2nd quarter worth $97,000. Hedge funds and other institutional investors own 6.67% of the company’s stock.

About Haleon

Haleon plc (NYSE: HLN) is a global consumer health company that develops, manufactures and markets over-the-counter medicines, oral health products, vitamins and supplements. Its portfolio is organized around categories including pain relief, respiratory health, digestive health, therapeutic oral care, everyday oral care, vitamins and minerals, and skin health.

Haleon’s well-known brands include Sensodyne, Polident, parodontax, Centrum, Advil, Voltaren, Panadol, Otrivin and Theraflu. The company’s products are sold through pharmacies, supermarkets, retailers and e-commerce channels, serving consumers in markets around the world.

Haleon was established as an independent consumer health business following its demerger from GSK in July 2022.